Abstract Background Erythromycin (EM) and rifampicin (RFP) have mainly been used to treat patients with
Introduction
In western countries, although new macrolides or fluoroquionorones are commonly used to treat Legionella disease (1, 2) , erythromycin (EM) 
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Materials and Methods
The study was performed retrospectively. 
Results
Nine patients treated with CPFX and eighteen patients treated with EM were eligible for this study. Overall, there were no significant differences in age, gender, comorbid illness and the duration of onset until treatment (Table 1) . Likewise, the severity of the pneumonia classified with each
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The mean time to apyrexia in the CPFX group tended to be shorter (3.5 (10) . In Western countries, CPFX has been used for the treatment of legionellosis for more than ten years (11, 12) . Recently in Japan, several case studies have been published on the successful treatment of legionellosis (1, 2) 
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